Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
April 1, 2025 7:29 AM EDTReported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx" administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial
Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx" in patients
with acute myocarditis, with topline data expected in Q2 2025
CardiolRx" granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,
which includes recurrent pericarditis
Cash and cash equivalents of $30.6 million as of December 31, 2024,
to fund operations into Q3... More
